Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Self-administered Subcutaneous Selatogrel for Prevention of All-cause Death and Treatment of Acute Myocardial Infarction in Subjects With a Recent History of Acute Myocardial Infarction

NCT04957719 is registered in ClinicalTrials.gov with Viatris Innovation GmbH as lead sponsor.

NCT NCT04957719
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04957719 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Efficacy and Safety of Self-administered Subcutaneous Selatogrel for Prevention of All-cause Death and Treatment of Acute Myocardial Infarction in Subjects With a Recent History of Acute Myocardial Infarction
Lead sponsor
Viatris Innovation GmbH
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
August 14, 2021
Completion date
July 31, 2027
Enrollment
25,000 (estimated)
Sites
821

Conditions

As the registry lists them; a condition with its own page is linked.

acute myocardial infarction